CBD Public Hearing Could Extend FDA's Hand Further For Help From Congress

Among comments submitted to FDA's docket in advance of public hearing May 31, National Organization for the Reform of Marijuana Laws' suggestions perhaps point to path ahead for agency. "Regulations governing the production, sale, quality, and marketing of these products must take place far more expeditiously in order to protect consumer safety," the group says. FDA already appealed to Congress in its notice about docket and hearing, says attorney Coleen Klasmeier. "The notice is really a comment directed to Congress."

CBD Molecule

More from Regulation

More from Policy & Regulation